On Oct. 26, MedImmune
- Revenues exceeded analyst estimates by 13.5%, while EPS outshone estimates by $0.07.
- Revenues increased 15.4% because of increased worldwide sales of Synagis and Flumist.
- Gross margin increased 152 bps to 69.8%.
- The increase in debt was a result of the company issuing $1,150 million in convertible senior notes, for total proceeds of $1,130 million.
- Cash increased 216.6% to $1,473 million.
- The company formed a new collaboration with Infinity Pharmaceuticals to develop small molecule cancer therapeutics.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Avg. Est. |
Q3 2006 |
Q3 2005 |
Change |
|
|---|---|---|---|---|
|
Sales |
$156 |
$177.2 |
$153.6 |
15.4% |
|
Net Profit |
-- |
($55.8) |
($64.1) |
N/A |
|
EPS |
($0.30) |
($0.23) |
($0.26) |
N/A |
|
Diluted Shares |
-- |
239.3 |
245.9 |
(2.7%) |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q3 2006 |
Q3 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
69.81% |
68.29% |
1.52 |
|
Operating Margin |
(72.63%) |
(67.58%) |
(5.05) |
|
Net Margin |
(31.49%) |
(41.73%) |
10.24 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$1,472.6 |
$465.2 |
216.6% |
|
Accounts Rec. |
$129.4 |
$137.3 |
(5.8%) |
|
Inventory |
$102.4 |
$91.7 |
11.7% |
|
Liabilities |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$38.5 |
$64.8 |
(40.6%) |
|
Long-Term Debt |
$1,165.8 |
$505.4 |
130.7% |
Learn the ways of the balance sheet.
Related Companies:
-
Biogen Idec
(NASDAQ:BIIB) -
Serono
(NASDAQ:SRA) -
Valeant Pharmaceuticals International
(NYSE:VRX)
Related Foolishness:
- MedImmune Is Easy to Resist
- Bristol-Myers and Sanofi Get Apotex to Stop
- What to Make of Bristol-Myers
Thirty-three Motley Fool CAPS players pick MedImmune to outperform the market. Six say it will underperform. Where do you stand? Join more than 11,500 fellow investors in the Fool's new stock-rating service and let your voice be heard . Biogen Idec is a Stock Advisor pick.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
